Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It was codiscovered by Dr. Marianne D Sadar and Dr. Raymond J Andersen. It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. It comprises a new pharmacological class recognized by United States Adopted Names (USAN) Council called antigens which are defined as a drug designed to bind to the androgen receptor N-terminal domain. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.
See also Masofaniten
References